VYGR

Voyager Therapeutics, Inc. is a biotechnology company. The Company focuses on leveraging its expertise in capsid discovery and neuropharmacology to address the delivery hurdles that have constrained the gene therapy and neurology disciplines. Its gene therapy platforms enable it to engineer, optimize, manufacture and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload. It has developed an AAV capsid discovery platform called Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACERTM) that employs directed evolution to facilitate the selection of AAV capsids with enhanced tissue delivery characteristics, such as more effective delivery across the blood brain barrier (BBB). Its pipeline programs include superoxide dismutase 1 (SOD1), gene therapy for amyotrophic lateral sclerosis (ALS), and an anti-tau antibody for Alzheimer’s disease.